A new spinoff from Jerusalem-based drug discovery company Pepticom will apply its artificial intelligence-based technology — used to discover and develop novel peptide molecules — for treating COVID-19. The spinoff, PeptiCov, has raised $2.6 million in a round led by the Chartered Group of Japan. Peptides are the hottest area of new drug development, particularly for diabetes and cancer. Medications […]
The post Peptide Discovery Firm Using AI To Find COVID-19 Drug first appeared on The Florida Star | The Georgia Star.
